About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, April 14th, 2015

The QualityStocks
Daily Stock List


Plandai Biotechnology, Inc. (PLPL)

WallstreetSurfers, SmallCapVoice, Stock Market Media Group, and Greenbackers reported earlier on Plandai Biotechnology, Inc. (PLPL), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Plandai Biotechnology, Inc. is a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical. The Company and its subsidiaries develop highly bioavailable, phytonutrient rich extracts. These are being used to deliver a new family of drugs to safely and affordably treat a host of diseases and conditions. Plandai Biotechnology lists on the OTCQB.

Plandai Biotechnology, via its wholly-owned subsidiaries, farms more than 8,500 acres of land in the Mpumalanga province of South Africa. It farms a full complement of produce, which it uses in its creation of highly bioavailable extracts, ranging from citrus to avocado pears to more than 2,000 acres of tea.

The Company delivers highly bioavailable, phytonutrient rich extracts under the trademark, Phytofare™. Plandai proprietary plant extracts have shown, in published studies, to have increased bioavailability. The Company believes through its studies that this is between 60-80 percent. This is significantly greater than anything now available.

Plandai’s extracts include, but are not limited to, gallate catechins from green tea, (catechin gallate (CG), epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), and epicatechin gallate (ECG); carotenoids (lycopene) from tomatoes, and also citrus bioflavonoids and limonoids. Moreover, its gallate catechin extract will be the active ingredient in formulated products supporting weight loss, antiaging, the lowering of blood cholesterol, the regulation of high blood pressure, and controlling diabetes 1 and 2.

Uruguay's Ministry of Public Health approved this past October an academic collaboration between Plandai and the Group of Medicinal Chemistry from the School of Science at the University of the Republic in Montevideo, Uruguay. Issued in September 2014, the approval permits Plandai Biotechnology to grow cannabis in combination with the University, for medical research, which will be undertaken by students and scientists from the School of Science at the University. Plandai Biotechnology - Uruguay, SA is a wholly-owned subsidiary of Plandai Biotechnology.

Plandai Biotechnology, Inc. (PLPL), closed Tuesday's trading session at $0.2399, up 4.76%, on 152,495 volume with 44 trades. The average volume for the last 60 days is 88,515 and the stock's 52-week low/high is $0.19/$0.8679.

LabStyle Innovations Corp. (DRIO)

TopPennyStockMovers reported this month on LabStyle Innovations Corp. (DRIO), SuperStockTips, Beacon Equity Research, Penny Stocks Finder, Stock Analyzer, Top Stock Picks, Penny Stock Craze, InvestorSoup, PennyStocks24, SuperNova Elite, and The MicrocapNews did earlier, and today we highlight the Company, here at the QualityStocks Daily Newsletter.

LabStyle Innovations Corp. is the developer of Dario™, a cloud-based, mobile health platform for diabetes and blood glucose monitoring. The Company is a mobile health (mHealth) enterprise developing and commercializing patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. Its flagship product is the Dario™ Diabetes Management Solution.  The Company lists on the OTC Markets’ OTCQB. LabStyle Innovations is headquartered in Israel.

LabStyle Innovations established with a mission to advance the way consumers engage, monitor, and lead healthier lives via the commercialization of unique, self-diagnostic technologies and platforms. The Company’s Dario™ received CE mark certification in September 2013. The Company is pursuing patent applications in a number of areas covering the specific processes related to blood glucose level measurement and more general methods of rapid tests of body fluids utilizing mobile devices and cloud-based services.

The Dario™ diabetes management platform includes the novel Dario™ app, website software, and an 'all-in-one', pocket-sized, Dario™ blood glucose monitoring device that comes complete with lancet, strips and a glucose meter. The glucose meter connects to a smartphone and the feature rich Dario™ mobile and website applications. This enables patients, medical professionals, and caregivers to access and analyze data in real time and from histories.

LabStyle Innovations has released the Dario™ Diabetes Management App for Android smartphone users. The mobile application has the same user interface and features as the iOS Dario™ Application. The Dario mobile app is a complete, cloud-based solution for personal diabetes management. It gives an individual and their support network real-time tools and actionable information. As a result, this makes it easy for a person to track and better understand their glucose levels.

LabStyle Innovations has now started the worldwide launch of its Dario Diabetes Management System. The expectation is that the worldwide blood glucose monitoring market will reach $12 Billion by 2017. The U.S. Patent and Trademark Office (USPTO) granted LabStyle a patent covering core functions of the Dario™. Dario™ has launched in the United Kingdom, New Zealand, Netherlands, and Australia. LabStyle Innovations recorded its first revenues in Q4 2014 from sales of Dario™.

LabStyle Innovations Corp. (DRIO), closed Tuesday's trading session at $0.395, down 8.14%, on 374,352 volume with 104 trades. The average volume for the last 60 days is 86,299 and the stock's 52-week low/high is $0.1001/$9.05.

AMP Holding, Inc. (AMPD)

TopPennyStockMovers and SmallCapVoice reported recently on AMP Holding, Inc. (AMPD), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

AMP Holding, Inc. is the parent company of AMP Electric Vehicles, Inc. and AMP Trucks, Inc.  AMP engages in the design, engineering, marketing, and sale of modified automobiles with an all-electric power train and battery systems. AMP Holding has its head office in Loveland, Ohio. The Company also has an office in Rochester, Michigan and its Workhorse Chassis Assembly Plant in Union City, Indiana. AMP's factory has the capacity to produce 60,000 vehicles annually.

AMP converts existing internal combustion engine based vehicles to all electric power trains, and provides original equipment manufacturers (OEMs) with its designed and integrated modular electric components. In addition, it provides electric power train engineering to end-users. The Company’s method to building its battery electric power trains utilizes proven, automotive-grade, mass-produced parts coupled with its custom designed, proprietary control software.

Its Amp Electric Vehicles manufactures electric drive systems for medium-duty, class 3-6 commercial truck platforms. Its AMP Trucks bought the assets of Workhorse Custom Chassis LLC from Navistar in March of 2013. AMP Trucks can equip its Workhorse chassis with gasoline, propane, or CNG engines. The acquisition of the Workhorse brand and the assembly plant in Union City enables AMP Trucks to manufacture new, medium-duty truck chassis in the 14,500 to 23,500 GVW class.

The U.S. Environmental Protection Agency (EPA) has approved AMP Holding’s WORKHORSE E-GEN™ electric truck. This truck uses an alternatively-fueled 2.4 liter engine as an emergency generator to charge the battery pack. AMP Holding has also successfully completed the build of its prototype E-GEN™ Electric Truck. The new truck is operational.

The ultra-efficient E-GEN Truck is fully EPA approved. It incorporates a small spark-ignition engine as an emergency generator, which automatically turns on to recharge the battery pack only if the pack's state of charge falls below a predetermined threshold, the drive selector is in “park” and the key is out, usually when the driver is in making deliveries.

Regarding Workhorse, it offers the AMP Electric Repower Program for fleet managers who want to retrofit their existing diesel powered vehicles. The diesel engine and ICE components are removed from the vehicle and replaced with the AMP electric drive train.

Today, AMP Holding announced that the United States Postal Service (USPS) has informed AMP that it has advanced in the Next Generation Delivery Vehicle (NGDV) program as a prequalified supplier. AMP had submitted information outlining the potential cost savings to the USPS of making deliveries in the AMP Workhorse E-GEN™ electric truck.

Mr. Steve Burns, AMP Chief Executive Officer, said, "We have always considered ourselves a next generation vehicle manufacturer. It is an honor for us to move to the next step in this important Post Office program."

AMP Holding, Inc. (AMPD), closed Tuesday's trading session at $0.38, down 2.56%, on 216,541 volume with 44 trades. The average volume for the last 60 days is 89,446 and the stock's 52-week low/high is $0.08/$0.40.

Medbox, Inc. (MDBX)

The Street, SmallCapVoice, and StreetInsider reported earlier on Medbox, Inc. (MDBX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medbox, Inc. is a foremost dispensary infrastructure/licensing specialist, patented technology provider, as well as partner to the cannabis industry. The Company, by way of its wholly-owned subsidiary, Medicine Dispensing Systems, provides its patented systems, software and consulting services to pharmacies, alternative medicine dispensaries, and local governments in the United States. Medbox has its corporate headquarters in Los Angeles, California and the Company lists on the OTCQB.

Medbox employs its expertise to work with investors and entrepreneurs who look to enter the cannabis sector. Medbox provides them with a high quality, turn-key solution, consisting of licensing, site selection, permitting, design, and full build-out. The Company has become a leader in providing compliance, safety, security, oversight and operational expertise to the medical and recreational cannabis industry nationally.

The Company also has its wholly-owned subsidiary, Vaporfection International, Inc. Through this subsidiary, it offers an industry award winning medical line of vaporizer products.

Through its newly established subsidiaries, Medbox is also developing supplementary services customized to the alternative medicine industry. This includes real estate acquisitions and subsequent lease programs to alternative medicine dispensaries and cultivation centers, and alternative medicine dispensary and cultivation management services. Medbox also engages in merchant services and armored transport for cash deposits (ancillary services catered to the alternative medicine industry).

Medbox features patented systems that dispense medication based on biometric identification (fingerprint sample). Its systems permit pharmacies, assisted living facilities, prisons, hospitals, doctors’ offices, and alternative medicine clinics to help manage employee possession of sensitive drugs.

In a retail environment characteristic in most alternative medicine clinics, the system lets the clinics document that the user is a registered patient and that the patient has a valid and unexpired authorization from a physician to possess and use the medicine dispensed.

Medbox has its patented “Medbox”. The biometrically sealed inventory control, storage and dispensing technology ensures safe and secure access to marijuana in medical and recreational dispensaries.

Medbox announced in November 2014 that its clients were awarded 8 cultivation provisional license approvals in Nevada. Medbox had filed 16 dispensary and cultivation center applications in Nevada for its clients and influential individuals in Nevada who have been appointed to the future dispensaries’ and cultivation centers’ Board of Directors. All applicants have engaged Medbox Management Services, which is a wholly-owned Medbox subsidiary, to provide continuing management services.

Medbox, Inc. (MDBX), closed Tuesday's trading session at $1.13, even for the day, on 306,083 volume with 164 trades. The average volume for the last 60 days is 340,102 and the stock's 52-week low/high is $1.05/$26.53.

Medican Enterprises, Inc. (MDCN)

TopPennyStockMovers, PennyStocks24, and Pennybuster reported on Medican Enterprises, Inc. (MDCN), and we choose to report on the Company as well, here at the QualityStocks Daily Newsletter.

Medican Enterprises, Inc. is a bio-pharmaceutical company, which focuses on going after business opportunities in the emerging medical and recreational marijuana sector. Through its subsidiaries, the Company is looking to invest in its businesses associated with the growing, marketing, research and development (R&D), training, distribution and retail sale of medical and recreational marijuana in the U.S. and Canada. Medican Systems is the wholly-owned operating subsidiary of Medican Enterprises.

Medican Enterprises is based in Las Vegas, Nevada. The Company lists on the OTC Markets Group’s OTCQB. The 67,000 square foot facility it is acquiring in Phoenix, Arizona has received zoning approval. It is now zone compliant for the operation of legal medical marijuana businesses.

Medican’s emphasis is on cultivating strains of Cannabis with standardized potencies and verified purity: High THC / Low CBD; Medium THC / Low CBD; Medium THC / Medium CBD; and Low TCH / High CBD. Pertaining to Financial Consulting, Medican provides strategic planning, valuation, project debt, and corporate finance solutions to its joint venture (JV) Partners. This is to capitalize on the growing MMJ market and fund multiple facilities.

Its Medican Systems is the operating arm of Medican Enterprises’ Medical Marijuana Cultivation and Research Facilities. Medican Systems is working to become one of Canada’s first commercially Licensed Producers of Medical Marijuana (MMJ) under the new program Marijuana for Medical Purposes Regulation (MMPR).

Medican has formed Medican (US) Systems, Inc., a wholly-owned subsidiary established to pursue business activities in the U.S. medical marijuana and recreational marijuana sectors. The new subsidiary looks for investments in commercial real estate, which it can lease to marijuana growers in states where growing is legal; and provide dispensary management and professional consulting services to the medical marijuana and recreational marijuana sectors. Furthermore, it will offer a broad array of leasing and financing solutions to dispensaries, kitchens, as well as cultivations centers.

Medican Enterprises’ announced this past October that its wholly-owned subsidiary, Medican Systems, entered into a binding Letter of Intent (LOI) to acquire Future Harvest Development Ltd. Under the terms of the LOI, Medican Systems will acquire a 70 percent interest in Future Harvest, with an option to acquire the remaining 30 percent. Future Harvest Development is a leading Canadian manufacturing company in the home and garden, indoor growing, and hydroponic sectors.

Medican Enterprises has formed a new wholly-owned subsidiary, Medican Nations, LLC. Medican Nations will center on building strategic partnerships with Indian communities in the U.S. and Canada to create and build business solutions within the indoor gardening and marijuana industries.

Medican Enterprises, Inc. (MDCN), closed Tuesday's trading session at $0.0145, up 28.32%, on 19,673,136 volume with 367 trades. The average volume for the last 60 days is 33,352,908 and the stock's 52-week low/high is $0.0007/$4.36.

Payment Data Systems, Inc. (PYDS)

StockGuru, Nebula Stocks, AllPennyStocks, FeedBlitz, OTC Picks, MicrocapVoice, and OTCReporter reported on Payment Data Systems, Inc (PYDS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

San Antonio, Texas-based Payment Data Systems, Inc. is an integrated payment solutions provider to merchants and billers. It provides a wide-ranging set of products to deliver world-class payment acceptance. The Company delivers its innovative solutions via three separate but technically integrated companies. All of these are fully PCI/DSS certified Level One Processors and are wholly-owned subsidiaries of Payment Data Systems. Payment Data Systems lists on the OTCQB.

The Company has solutions for merchants, billers, banks, service bureaus, and card issuers. Its strength is its ability to offer specifically tailored solutions for card issuance, payment acceptance, and bill payments. Payment Data Systems centers on the processing of payments for merchants and large enterprises.

The design of the Company’s products are to provide payment solutions wherever a business’s customer happens to be or however they need to pay; by phone to a business’s Customer Service Department, at its website, by Interactive Voice Response (IVR), by retail terminal, or by mobile payments.

Payment Data Systems is acquiring largely all of the assets of Akimbo Financial, Inc. of San Antonio, Texas. The Company expects to complete the acquisition in the near future. The agreed purchase price is a total of $3 million. It is to be paid primarily in common stock in two tranches, with a cash component of up to $300,000 if any liabilities are assumed.

Today, Payment Data Systems announced that it attained record transaction processing in Q1 2015. Credit card processing volumes for Q1 2015 were the third highest for any quarter in the history of the Company. Credit cards dollars processed during Q1 2015 were up 8 percent over the same period in 2014. Credit cards transactions processed during Q1 2015 were up 3 percent over the same period the year prior.

Electronic check transaction volumes in Q1 2015 were the second highest for any quarter in the history of Payment Data Systems. Electronic check transaction volumes during Q1 2015 were up 61 percent over the same period in 2014. Returned check transactions processed during Q1 2015 were up 39 percent over the same period the year prior. Total dollars processed for Q1 2015 exceeded $797,900,000 and is the second highest for any quarter in the history of the Company.

Payment Data Systems, Inc (PYDS), closed Tuesday's trading session at $0.368, up 8.24%, on 154,106 volume with 37 trades. The average volume for the last 60 days is 200,201 and the stock's 52-week low/high is $0.071/$0.44.

Builders FirstSource, Inc. (BLDR)

INO.com Market Report reported recently on Builders FirstSource, Inc. (BLDR), StreetInsider, Daily Gains Newsletter, SmarTrend Newsletters, InvestorPlace, and Profit Confidential did earlier, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Founded in 1998, Builders FirstSource, Inc. is a foremost supplier and manufacturer of structural and related building products for residential new construction in the U.S. The Company operates 56 distribution centers and 56 manufacturing facilities in nine states. These are mainly in the southern and eastern U.S.  Builders FirstSource has its corporate headquarters in Dallas, Texas. The Company’s shares trade on the Nasdaq Global Select market.

Builders FirstSource’s manufacturing facilities include plants that manufacture roof and floor trusses, wall panels, stairs, aluminum and vinyl windows, custom millwork and pre-hung doors. In addition, the Company distributes windows, interior and exterior doors, dimensional lumber and lumber sheet goods, millwork, as well as other building products.

Builders FirstSource works to be the leading supplier of structural building materials and services to homebuilders. The Company believes that the key to its success is its ability to provide personalized attention to its customers at the local level. This is while also providing its’ customers with the resources only offered by a large company.

Regarding distribution, Builders FirstSource distributes Adhesives & Sealants, Cabinets, Columns, Connectors, Cultured Stone, Decking, Doors, Drywall, Engineered Wood Products, Steel Trusses, Windows, Wood Trusses, and Garage Doors, It also distributes Hardware, House Wrap, Insulation, Interior Trim & Mouldings, Lumber & Treated Wood, Railings, Roofing, Sheathing, Shutters, Stairs and Siding.

The Company also provides installation for numerous products that it sells. Furthermore, it manufactures professional quality building components for the contemporary construction process. Builders FirstSource manufactures prefabricated structural components: roof trusses, floor trusses, stairs, and wall panels, and interior and exterior doors and windows.

Yesterday, Builders FirstSource announced that it entered into a definitive purchase agreement to acquire ProBuild Holdings LLC in an all-cash transaction valued at roughly $1.63 billion. The transaction, approved by the Builders FirstSource Board of Directors, is subject to customary closing conditions and regulatory approvals. The expectation is that the transaction will close in the second half of 2015.

ProBuild Holdings is one of the nation's largest professional building materials suppliers. ProBuild is one of the largest distributors of building materials to professional builders, contractors, as well as project-oriented consumers in the U.S. Builders FirstSource expects to generate $100 Million to $120 Million in annual cost savings with this acquisition. The acquisition creates a diversified national professional dealer with roughly $6 Billion in sales.

Mr. Floyd Sherman, Builders FirstSource CEO, said, "We are very pleased to announce this compelling combination with ProBuild to create a more diversified company with enhanced scale and an improved geographic footprint that will drive significant value for our customers and stockholders.”

Builders FirstSource, Inc. (BLDR), closed Tuesday's trading session at $13.59, up 17.46%, on 12,220,974 volume with 46,190 trades. The average volume for the last 60 days is 479,955 and the stock's 52-week low/high is $4.85/$11.74.


The QualityStocks
Company Corner


International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.054, up 8.00%, on 990,554 volume with 75 trades. The stock’s average daily volume over the past 60 days is 649,350, and its 52-week low/high is $0.045/$0.19.

International Stem Cell Corp. announced today that the company has been selected to give a platform presentation on its preclinical studies in Parkinson's at the 2015 American Academy of Neurology Annual Meeting in Washington, DC. ISCO's chief scientific officer, Ruslan Semechkin, Ph.D., will discuss the data at the "Parkinson's Disease" scientific session (s48.007), on Thursday, April 23rd at 4:45 pm in a talk entitled "Neural Stem Cell Based Therapy for Parkinson's Disease."

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.

The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.

In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Presents Data From Parkinson's Disease Program at AAN Annual Meeting

International Stem Cell Corporation Demonstrates Reversal of Neurological Stroke Symptoms Using Neural Stem Cells

International Stem Cell Corporation Announces 2014 Fourth Quarter and Year-End Results

IFAN Financial, Inc. (IFAN)

The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.1969, up 14.48%, on 146,974 volume with 54 trades. The stock’s average daily volume over the past 60 days is 380,092, and its 52-week low/high is $0.0114/$1.01.

IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.

Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.

Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.

IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer

IFAN Financial, Inc. Company Blog

IFAN Financial, Inc. News:

IFAN Financial, Inc. (IFAN) Expands Board of Directors With Addition of Technology Venture Veteran

IFAN Financial Applauds Facebook's Move Into the Mobile Payments Industry, Foresees Ancillary Opportunities

IFAN Financial Begins Beta Testing With Nation's Largest Debit Card Acquiring Processor

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.1999, up 9.18%, on 46,985 volume with 18 trades. The stock’s average daily volume over the past 60 days is 23,593, and its 52-week low/high is $0.13/$0.95.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial

Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible

Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device

Falcon Crest Energy (FCEN)

The QualityStocks Daily Newsletter would like to spotlight Falcon Crest Energy (FCEN). Today, Falcon Crest Energy closed trading at $0.016, up 5.26%, on 24,600 volume with 3 trades. The stock’s average daily volume over the past 60 days is 8,804, and its 52-week low/high is $0.0066/$0.095.

Falcon Crest Energy (FCEN) is a development stage oil and gas exploration and production company focused on developing properties in North America. The company plans to minimize the risk of exploration through development of proved petroleum reserves, and expects to maximize profit through strategic acquisition and liquidation of selected oil and gas properties.

The company specializes in acquiring low risk, high upside properties with substantial exploration potential. Through improvements in oil and gas production technologies, Falcon Crest Energy aims to rapidly increase production levels and generate predictable, sustainable value. The business strategy utilized calls for both 100% acquisitions and joint-ventures to maximize production capacity.

Evergreen Petroleum, a joint venture partner, is working closely with the company to explore oil-bearing formations in Wyoming. Evergreen has conducted and will continue to conduct both regional and local geological studies to define prospects that are worthy of acquiring oil and gas leases. By partnering with industry experts such as Evergreen, Falcon Crest Energy has strategically added extensive technical guidance and field management experience.

Even during challenging times, the world depends on oil & gas exploration and production companies to deliver millions of barrels of oil every day. Increased demand from emerging countries such as China further escalates competition for this precious resource. Backed by an experienced group of professionals, Falcon Crest Energy is well positioned to generate substantial revenues in the short and long term future. Disclaimer

Falcon Crest Energy Company Blog

Falcon Crest Energy News:

Falcon Crest Energy Acquires Remaining Working Interest in Rocky Ford Field

Falcon Crest Names Michael Cvetanovic to Advisory Council

Falcon Crest Energy Announces Powder River Basin Leasehold Acquisition

Pure Hospitality Solutions, Inc. (PNOW)

The QualityStocks Daily Newsletter would like to spotlight Pure Hospitality Solutions, Inc. (PNOW). Today, Pure Hospitality Solutions, Inc. closed trading at $0.0025, even for the day, on 394,933 volume with 4 trades. The stock’s average daily volume over the past 60 days is 576,811, and its 52-week low/high is $0.002/$0.6471.

Pure Hospitality Solutions, Inc. (PNOW) is a provider of proprietary technology, marketing solutions, infrastructure and branding services to hotel operators.

The company's innovative platform functions as a powerful vehicle to help hotel operators achieve greater success in three specific areas: (i) expanded international exposure and recognition, (ii) powerful core structure, and (iii) high occupancy rates that drive increases in bottom-line profits. Pure continuously refines its suite of proprietary solutions to deliver measurable and proven results to hotel properties. This success has been reflected in those properties operating under the Hotel PURE brand as well as with independent boutique hotel properties utilizing the company's Friendly Reservation Online (FROL) booking engine technology and internet marketing services.

Operating a successful bi-lateral business model, Pure has four objectives:

1. To franchise the Hotel PURE brand to selected hotel properties worldwide similar to the business model currently employed by Big Brand operators such as Holiday Inn, Marriott, Sheraton and others;

2. Provide highly efficient and economical back-end booking engine technology services to independently branded boutique hotels that require a robust online presence;

3. Launch a stand-alone online hotel booking search engine primarily focused on Central America; and,

4. Expand the portfolio of Pure-owned boutique hotels operating under the Hotel PURE brand.

The company initially began growing its operations primarily in the United States. However most recently, major opportunities in Central America began presenting themselves, giving Oriens the ability to retool its business model. Now the company is positioned to acquire, own and operate its own properties – which would be marketed under the new brand with occupancies handled by the re-launched online booking engine system.

Ultimately, Pure intends to become a top-tier hotel brand operator and Internet booking and marketing service provider, qualifying as a preferred supplier to lending institutions. The company also intends to establish an invaluable international footprint with its online booking engine technology and marketing offerings; making that segment of its business a prime acquisition target for major online travel search and booking engine companies. Advancement toward this goal is guided by an executive management team with deep expertise in technology, banking, management, hospitality, branding and marketing, technical development and more. Disclaimer

Pure Hospitality Solutions, Inc. Company Blog

Pure Hospitality Solutions, Inc. News:

National Tourism Center Of Costa Rica Gives Pure Opportunity

Pure's Oveedia Signs First Property

Pure Retains Softon to Accelerate Photo Share Software

MIT Holding (MITD)

The QualityStocks Daily Newsletter would like to spotlight MIT Holding (MITD). Today, MIT Holding closed trading at $0.0649, off by 0.15%, on 550 volume with 2 trades. The stock’s average daily volume over the past 60 days is 14,583, and its 52-week low/high is $0.032/$0.29.

MIT Holding (MITD), through its agents, facilitators and contractual obligations, offers professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery. The company is also pursuing government contacts to obtain approval to import pharmaceutical products into the Americas.

In support of these core services, MIT Holding provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Collectively, these services contribute to MIT Holding’s strategy to provide custom prescription solutions in a variety of methods and generate multiple revenue streams. Following a successful reorganization initiative in January, 2014, MIT Holding is positioned to achieve 32% minimum net profits and has maintained profitability in its fiscal second and third quarters. This profitability validates the company’s business model and its approach to the evolving Affordable Health Care Act and its impact on the health services industry.

MIT Holding meets and/or exceeds major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators. This ability marks an important step in the company’s goal of developing the first-of-its-kind seamless transition for patient needs from hospital discharge to complete home recovery. This and other corporate initiatives are spearheaded by a management team committed to building shareholder value, revenues and corporate expansion while providing viable solutions to the perpetual changes in the health care sector. Disclaimer

MIT Holding Company Blog

MIT Holding News:

MIT Holding (MITD) Launches New Website with Investor Relations Suite

MIT Holding, Inc. Names Tommy J. Duncan as President

MIT Holding, Inc. (MITD) Announces Engagement of QualityStocks Investor Relations Services

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $9.99, even for the day. The stock’s average daily volume over the past 60 days is 656, and its 52-week low/high is $3.16/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board

VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Wall Street Resources


Fast Money Alerts



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251